Prevalence estimates for chronic urticaria in the United States: A sex- and age-adjusted population analysis - 21/06/19
Abstract |
Background |
Disease burden in chronic urticaria (CU) is poorly understood.
Objective |
To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.
Methods |
A cross-sectional analysis with electronic health records data for a demographically heterogeneous population-based sample of >55 million patients across all 4 census regions.
Results |
The overall CU prevalence was 0.23%, or 230 CU cases/100,000 adults. The adjusted prevalence in women was 310 (95% confidence interval [CI] 307-312) cases/100,000 adults, more than twice that of men (146 [95% CI 143-148] cases/100,000 adults, P < .001). CU prevalence was highest among patients aged 40-49 years (256 [95% CI 252-261] cases/100,000 adults) and 50-59 years (246 [95% CI 242-251] cases/100,000 adults) compared with all other age groups (P < .0001). Adjusted prevalences for black (292 [95% CI 285-298] cases/100,000 adults) and other (331 [95% CI 323-338] cases/100,000 adults) patients were higher than that for white patients (262 [95% CI 260-264] cases/100,000 adults; P < .001).
Limitations |
Use of administrative data has the potential to underestimate burden.
Conclusion |
There are >500,000 people estimated to have CU in the United States, most of whom are women or adults ≥40 years of age.
Le texte complet de cet article est disponible en PDF.Key words : burden of disease, chronic urticaria, Explorys, population-based, prevalence, urticaria
Abbreviations used : CI, CU, ICD, SNOMED-CT
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Garg has served as an advisor for AbbVie, Pfizer, Janssen, and Asana Biosciences and received honoraria. Ms Wertenteil and Mr Strunk have no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
Vol 81 - N° 1
P. 152-156 - juillet 2019 Retour au numéro
Article précédent
- Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
- Sarah Faiz, Jonathan Giovannelli, Céline Podevin, Marie Jachiet, Jean-David Bouaziz, Ziad Reguiai, Audrey Nosbaum, Audrey Lasek, Marie-Christine Ferrier le Bouedec, Aurélie Du Thanh, Nadia Raison-Peyron, Florence Tetart, Anne-Bénédicte Duval-Modeste, Laurent Misery, François Aubin, Anne Dompmartin, Cécile Morice, Catherine Droitcourt, Angèle Soria, Jean-Philippe Arnault, Juliette Delaunay, Emmanuel Mahé, Marie-Aleth Richard, Amélie Schoeffler, Jean-Philippe Lacour, Edouard Begon, Amélie Walter-Lepage, Anne-Sophie Dillies, Sandrine Rappelle-Duruy, Stéphane Barete, Nathalia Bellon, Nathalie Bénéton, Aude Valois, Sébastien Barbarot, Julien Sénéchal, Delphine Staumont-Sallé, Groupe de Recherche sur l'Eczéma aTopique (GREAT), France
- Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis
- Molly Stout, Jonathan I. Silverberg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?